Your browser doesn't support javascript.
loading
Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study.
Jia, Meng; Jia, Jiang-Kun; Xu, Jian; Xue, Huan-Zhou.
Affiliation
  • Jia M; Department of Hepatobiliary Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, People's Republic of China.
  • Jia JK; Department of Hepatobiliary Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, People's Republic of China.
  • Xu J; Department of Hepatobiliary Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, People's Republic of China.
  • Xue HZ; Department of Hepatobiliary Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, People's Republic of China.
Cancer Manag Res ; 14: 2625-2638, 2022.
Article in En | MEDLINE | ID: mdl-36081824
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancer Manag Res Year: 2022 Document type: Article Country of publication: New Zealand
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancer Manag Res Year: 2022 Document type: Article Country of publication: New Zealand